Search Results for: stem cells for ms

Jacob Hanna on Radically Deterministic Reprogramming @TMM2013

When Jacob Hanna  says “radically deterministic” cellular reprogramming, what does he mean? Jacob Hanna’s lab recently published a very high profile Nature paper on nearly 100% efficient iPS cell formation based on targeting a factor called Mbd3. This super efficiency is a major departure from past reported efficiencies. This morning here at the Till &

Jacob Hanna on Radically Deterministic Reprogramming @TMM2013 Read More »

100% reprogramming efficiency reports Jacob Hanna

A team at the Weizmann Institute of Science in Israel led by Jacob Hanna reports today near perfect reprogramming efficiency to make induced pluripotent stem cells (iPSCs) by eliminating a single factor called Mbd3 from the cellular equation. On first glance, the Nature article (Rais, et al.) seems to be all about boosting cellular reprogramming efficiency to close

100% reprogramming efficiency reports Jacob Hanna Read More »

Want to 3D Print Yourself a New Organ? Key Challenges

3D-printer-300x2751

Need a new liver, pancreas, or other vital organ, then I’ll 3D print one right up for you…that is in about 10 years. My intern Lakshmi did a great job on her guest piece last week on the promise of 3D printing in stem cell-based bioengineering including organ and tissue production. It’s an incredibly exciting area of

Want to 3D Print Yourself a New Organ? Key Challenges Read More »

Interview with Dr. Steven Victor of IntelliCell Biosciences (SVFC)

Steven-Victor-250x3001

What’s the deal with IntelliCell Biosciences, headed up by Dr. Steven Victor? Sometimes science can move at warp speed and that is even more true of the stem cell field. One stem cell establishment that seems to be in a particularly intense period of activity and that has drawn a great deal of attention lately

Interview with Dr. Steven Victor of IntelliCell Biosciences (SVFC) Read More »

New FDA IntelliCell BioSciences, Audit Report: A Lot of Work to Do

IntelliCell BioSciences, Inc. of New York, a clinical stem cell establishment, has had a rough time of it lately. For example, a recent piece of bad news is that there is an impending foreclosure sale of the company’s assets. What exactly that means for the company more broadly remains unknown, but a few people tell me (take this

New FDA IntelliCell BioSciences, Audit Report: A Lot of Work to Do Read More »